Zobrazeno 1 - 10
of 166
pro vyhledávání: '"Kengo Azushima"'
Autor:
Eriko Abe, Akio Yamashita, Keigo Hirota, Takahiro Yamaji, Kengo Azushima, Shingo Urate, Toru Suzuki, Shohei Tanaka, Shinya Taguchi, Shunichiro Tsukamoto, Tatsuki Uehara, Hiromichi Wakui, Kouichi Tamura, Hidehisa Takahashi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-14 (2022)
Abstract Kidney fibrosis is a common pathway that leads to chronic kidney disease. Angiotensin II type-1 receptor (AT1R)-associated protein (ATRAP) was originally identified as an AT1R-binding protein. Previously, we reported that systemic knockout o
Externí odkaz:
https://doaj.org/article/71c7295333634ee197823258f0af8601
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 8 (2023)
The incidence of heart failure and chronic kidney disease is increasing, and many patients develop both diseases. Angiotensin receptor‐neprilysin inhibitor (ARNI) is a promising therapeutic candidate for both diseases. ARNI has demonstrated superio
Externí odkaz:
https://doaj.org/article/cd819953d60e42d380a3579751142fb2
Autor:
Shinya Taguchi, Kengo Azushima, Takahiro Yamaji, Shingo Urate, Toru Suzuki, Eriko Abe, Shohei Tanaka, Shunichiro Tsukamoto, Daisuke Kamimura, Sho Kinguchi, Akio Yamashita, Hiromichi Wakui, Kouichi Tamura
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Tumor necrosis factor (TNF)-α is a potent mediator of inflammation and is involved in the pathophysiology of chronic kidney disease (CKD). However, the effects of TNF-α inhibition on the progression of kidney fibrosis have not been fully e
Externí odkaz:
https://doaj.org/article/64c0cab936974988914bfdbf50e94cf4
Autor:
Yuki Kawai, Yoshiyuki Toya, Hiromichi Wakui, Tetsuya Fujikawa, Eiko Ueda, Kengo Azushima, Sho Kinguchi, Hiroshi Mitsuhashi, Tomoyuki Kawano, Tadashi Kuji, Satoshi Yamaguchi, Toshimasa Ohnishi, Kouichi Tamura
Publikováno v:
Journal of Pharmacological Sciences, Vol 147, Iss 1, Pp 118-125 (2021)
Our previous randomized controlled trial comparing the total dose of weekly versus biweekly continuous erythropoietin receptor activator (CERA) therapy to maintain optimal hemoglobin (Hb) levels showed no significant differences between the two thera
Externí odkaz:
https://doaj.org/article/bc8b5ab08cbb441db2084058f0dfc4de
Autor:
Shunichiro Tsukamoto, Hiromichi Wakui, Kengo Azushima, Takahiro Yamaji, Shingo Urate, Toru Suzuki, Eriko Abe, Shohei Tanaka, Shinya Taguchi, Takayuki Yamada, Sho Kinguchi, Daisuke Kamimura, Akio Yamashita, Daisuke Sano, Masayuki Nakano, Tatsuo Hashimoto, Kouichi Tamura
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract Elevated angiotensin-converting enzyme 2 (ACE2) expression in organs that are potential targets of severe acute respiratory syndrome coronavirus 2 may increase the risk of coronavirus disease 2019 (COVID-19) infection. Previous reports show
Externí odkaz:
https://doaj.org/article/cc4d3bcac09c4ff7b0e11d641e7e432c
Autor:
Kazushi Uneda, Yuki Kawai, Takayuki Yamada, Sho Kinguchi, Kengo Azushima, Tomohiko Kanaoka, Yoshiyuki Toya, Hiromichi Wakui, Kouichi Tamura
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Patients with type 2 diabetes mellitus (T2DM) and obesity are at high risk of developing cardiovascular disease (CVD). Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter (SGLT-2) inhibitors have been
Externí odkaz:
https://doaj.org/article/bdeeefe0317c4f1680ebe0f2d15b978a
Autor:
Eriko Abe, Akio Yamashita, Keigo Hirota, Takahiro Yamaji, Kengo Azushima, Shingo Urate, Toru Suzuki, Shohei Tanaka, Shinya Taguchi, Shunichiro Tsukamoto, Tatsuki Uehara, Hiromichi Wakui, Kouichi Tamura, Hidehisa Takahashi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-2 (2022)
Externí odkaz:
https://doaj.org/article/8510f9a073ab45f58a9a59a2a189e047
Autor:
Shunichiro Tsukamoto, Shingo Urate, Takayuki Yamada, Kengo Azushima, Takahiro Yamaji, Sho Kinguchi, Kazushi Uneda, Tomohiko Kanaoka, Hiromichi Wakui, Kouichi Tamura
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Tolvaptan is the gold standard treatment for autosomal dominant polycystic kidney disease (ADPKD), while several other drugs have the potential to inhibit the progression of ADPKD. However, individual clinical trials may not show sufficie
Externí odkaz:
https://doaj.org/article/509e64296a924249a78245e9c0246d55
Autor:
Yuki Kawai, Yoshiyuki Toya, Hiromichi Wakui, Tetsuya Fujikawa, Eiko Ueda, Kengo Azushima, Hiroshi Mitsuhashi, Tomoyuki Kawano, Tadashi Kuji, Satoshi Yamaguchi, Toshimasa Ohnishi, Kouichi Tamura
Publikováno v:
The Journal of Clinical Hypertension, Vol 23, Iss 4, Pp 870-878 (2021)
Abstract Although continuous erythropoietin receptor activators (CERAs) are widely used erythropoiesis‐stimulating agents for correcting renal anemia in patients undergoing hemodialysis (HD), few reports have examined weekly CERA administration. In
Externí odkaz:
https://doaj.org/article/62f0e25c3ca842bebc112335d5734937
Autor:
Shohei Tanaka, Hiromichi Wakui, Kengo Azushima, Shunichiro Tsukamoto, Takahiro Yamaji, Shingo Urate, Toru Suzuki, Eriko Abe, Shinya Taguchi, Takayuki Yamada, Ryu Kobayashi, Tomohiko Kanaoka, Daisuke Kamimura, Sho Kinguchi, Masahito Takiguchi, Kengo Funakoshi, Akio Yamashita, Tomoaki Ishigami, Kouichi Tamura
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 9, p 7778 (2023)
Considering the prevalence of obesity and global aging, the consumption of a high-protein diet (HPD) may be advantageous. However, an HPD aggravates kidney dysfunction in patients with chronic kidney disease (CKD). Moreover, the effects of an HPD on
Externí odkaz:
https://doaj.org/article/24a1394843734b3cad2014fbb1180531